Avalanche Biotechnologies, Inc. (Avalanche) is a biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Avalanche has leveraged its next generation gene therapy platform, the Ocular BioFactory, to create a robust pipeline of product candidates. Its product candidates are designed to provide long-term benefit or a functional cure for these diseases by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye. The Company�s products include AVA-101, AVA-201, AVA-311, AVA-322 and AVA-323. AMD is a progressive disease affecting the retinal cells in the macula, the region of the eye responsible for central vision. Disease progression results in the death of retinal cells and the gradual loss of vision. As people age, the likelihood of disease progression increases and the resulting condition is referred to as AMD.